World News: 16:45 GMT Tuesday 3rd December 2019. [INVENTIVA via Globe Newswire via SPi World News]
The clinical study initiated by AbbVie with ABBV-157 is a randomized, double-blind, placebo-controlled study in which patients with moderate to severe chronic plaque psoriasis will be administered multiple oral doses of the drug candidate.
In 2012, Inventiva and AbbVie signed a multi-year drug discovery collaboration to identify potent RORγ inverse agonists for the treatment of several auto-immune diseases. Through this collaboration, Inventiva leverages its discovery expertise and technology platforms to develop drug candidates targeting the nuclear receptor RORy, a validated drug target for the treatment of cutaneous inflammatory disorders such as psoriasis. In the area of auto-immune diseases, Inventiva focuses its research and development on compounds that differentiate themselves by greater convenience, greater efficacy and potentially better safety/tolerability compared to biological agents, which are the current standard of care.
The collaboration between Inventiva and AbbVie entitles the Company to receive further milestone payments and royalties on future sales of ABBV-157.
Psoriasis is a common skin disease with an estimated prevalence ranging from 0.9% to 8% of the world’s population, depending on the countries. In moderate and severe cases, psoriatic lesions can be uncomfortable, itchy and disfiguring. Although the precise pathophysiology of psoriasis is unknown, an abnormal cutaneous immunologic/inflammatory response, associated with epidermal hyper proliferation and abnormal differentiation, seems to be involved.
Current treatment of psoriasis is directed toward the alteration of epidermal differentiation, reducing the inflammatory response and slowing the growth of involved skin cells. The extent and severity of the disease typically determine the therapeutic approach. However, the current treatment of psoriasis can only provide skin clearance but not a cure. In mild psoriasis, the most commonly used therapy is topical with the addition of phototherapy in refractory cases. In moderate to severe psoriasis, phototherapy, systemic therapy, or a combination of the two is recommended. Systemic treatments include acitretin, cyclosporin and methotrexate, or biologic agents such as anti-TNFa.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates – lanifibranor and odiparcil – in non-alcoholic steatohepatitis (“NASH”) and mucopolysaccharidosis (“MPS”), respectively, as well as a deep pipeline of earlier stage programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease. Inventiva is currently evaluating lanifibranor in a Phase IIb clinical trial for the treatment of this disease for which there are currently no approved therapies.
Inventiva is also developing odiparcil, a second clinical‑stage asset, for the treatment of patients with MPS, a group of rare genetic disorders. The Company is currently investigating odiparcil in a Phase IIa clinical trial for the treatment of patients with the MPS VI subtype.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic partnership with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development phase of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration entitles Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from this partnership.
The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology a well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, around 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012).
Globe Newswire: 16:45 GMT Tuesday 3rd December 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.